Dow Jones

38 686,32

1,51%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
USOTC
Sigyn Therapeutics Inc (QB) (SIGY)
Sigyn Therapeutics Inc (QB) (SIGY) Actualités

SIGY

Sigyn Therapeutics (QB) (SIGY)

Sigyn Therapeutics Inc (QB)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:USOTC:SIGY

Date	Heure	Source	Titre	Symbole	Société
31/01/2024	22h20	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
14/08/2023	21h35	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
08/06/2023	20h38	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
17/05/2023	13h15	InvestorsHub NewsWire	Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep™ Trademark Application	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
15/05/2023	23h35	Edgar (US Regulatory)	Quarterly Report (10-q)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
10/05/2023	23h27	Edgar (US Regulatory)	Securities Registration Statement (s-1/a)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
31/03/2023	16h06	InvestorsHub NewsWire	Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
31/03/2023	12h19	Edgar (US Regulatory)	Annual Report (10-k)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
14/09/2022	18h37	InvestorsHub NewsWire	Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
03/08/2022	13h07	InvestorsHub NewsWire	Sigyn Therapeutics to Commence Trading on the OTCQB® Venture Exchange	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
23/06/2022	12h02	Edgar (US Regulatory)	Securities Registration Statement (s-1)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
23/05/2022	11h00	TipRanks	Analysts Are Bullish on These Healthcare Stocks: Sigyn Therapeutics (SIGY)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
04/02/2022	16h48	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
17/12/2021	14h48	InvestorsHub NewsWire	Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
26/10/2021	16h43	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
10/08/2021	13h18	InvestorsHub NewsWire	Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
29/07/2021	16h19	InvestorsHub NewsWire	Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
15/07/2021	14h00	InvestorsHub NewsWire	Sigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood Plasma	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
28/06/2021	15h48	InvestorsHub NewsWire	The Evolution of Blood Purification Technologies to Treat Emerging Pandemic Threats, Including COVID-19	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
31/03/2021	18h49	Edgar (US Regulatory)	Notification That Annual Report Will Be Submitted Late (nt 10-k)	USOTC:SIGY	Sigyn Therapeutics Inc (QB)
02/11/2020	14h41	InvestorsHub NewsWire	Sigyn Therapeutics (SIGY) CEO Note: Rethinking the Treatment of Sepsis and Other Life-Threatening Inflammatory Conditions	USOTC:SIGY	Sigyn Therapeutics Inc (QB)